Join
Live feed
·
PRReleasevia Quantisnow
Medicus Pharma Ltd. logo

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
MDCX· Medicus Pharma Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MDCX (Medicus Pharma Ltd.) and more on Quantisnow.